Ryght Company Profile

Background

Overview

Ryght is a privately held healthcare technology company specializing in generative artificial intelligence (GenAI) solutions tailored for the life sciences industry. Founded in 2023 and headquartered in Laguna Beach, California, Ryght focuses on enhancing clinical research processes through advanced AI technologies. The company's mission is to accelerate clinical trials, improve patient outcomes, and expedite the delivery of life-saving therapies to the market. Ryght's vision is to revolutionize clinical research by providing secure, AI-driven platforms that streamline operations and foster innovation.

Industry Significance

Ryght addresses critical challenges in the clinical research sector, including inefficiencies in site selection, patient recruitment, and trial management. By leveraging AI, Ryght aims to reduce administrative burdens, shorten trial timelines, and enhance the accuracy of clinical studies, thereby contributing to the advancement of medical research and patient care.

Key Strategic Focus

Core Objectives

• Accelerate Clinical Trials: Utilize AI to streamline site selection, feasibility assessments, and patient recruitment, thereby reducing trial durations.

• Enhance Data Security: Develop secure platforms that comply with industry standards to protect sensitive healthcare data.

• Foster Innovation: Integrate cutting-edge AI technologies to drive advancements in clinical research methodologies.

Areas of Specialization

• Clinical Trial Optimization: Implement AI solutions to improve site performance, patient enrollment, and overall trial efficiency.

• Generative AI Applications: Develop AI-driven tools for data analysis, predictive modeling, and decision support in clinical research.

Key Technologies Utilized

• Large Language Models (LLMs): Employ advanced LLMs to process and interpret complex biomedical data.

• Vector Databases: Utilize vector databases for efficient data storage and retrieval, enhancing AI model performance.

• AI Site Twins: Create digital replicas of clinical research sites to simulate and predict trial outcomes.

Primary Markets Targeted

• Biopharmaceutical Companies: Provide solutions to optimize drug development processes.

• Contract Research Organizations (CROs): Offer tools to enhance trial management and execution.

• Healthcare Data Organizations: Support data-driven decision-making through advanced analytics.

Financials and Funding

Funding History

Ryght has secured multiple funding rounds to support its growth and technological development:

• Seed Funding (June 2025): Raised $3 million from AIX Ventures and six other investors.

• Seed Funding (November 2023): Raised $2.5 million from Iaso Ventures.

Utilization of Capital

The funds are allocated towards:

• Product Development: Enhancing AI capabilities and expanding the platform's features.

• Market Expansion: Establishing partnerships and entering new markets.

• Operational Scaling: Building infrastructure to support a growing global network.

Pipeline Development

Key Pipeline Candidates

Ryght is developing several AI-driven applications aimed at transforming clinical research:

• AI Site Twins: Digital replicas of clinical research sites to simulate and predict trial outcomes.

• Feasibility Accelerator: Automated tools for rapid site selection and feasibility assessments.

• Network Navigator: Platform to connect sponsors with optimal research sites globally.

Stages of Development

These applications are in various stages, from conceptualization to beta testing, with plans for broader deployment in the near future.

Target Conditions

The technologies are designed to address challenges across multiple therapeutic areas, including oncology, cardiology, and neurology.

Anticipated Milestones

• Beta Releases: Scheduled for late 2025.

• Full Deployment: Planned for mid-2026.

Technological Platform and Innovation

Proprietary Technologies

• AI Site Twins: Digital replicas of clinical research sites to simulate and predict trial outcomes.

• Feasibility Accelerator: Automated tools for rapid site selection and feasibility assessments.

• Network Navigator: Platform to connect sponsors with optimal research sites globally.

Significant Scientific Methods

• Machine Learning Algorithms: For predictive modeling and data analysis.

• Natural Language Processing (NLP): To interpret and process unstructured biomedical data.

Leadership Team

Key Executives

• Simon Arkell: Co-founder and CEO. Formerly CEO of Synthetica Bio, leading the company's rebranding to Ryght.

• Chadi Nabhan, MD, MBA: Chief Medical Officer and Head of Strategy. Previously Chief Medical Officer at Cardinal Health.

• Johnny Crupi: Chief Technology Officer and Co-founder. Former CTO at Synthetica Bio.

Key Contributions

• Simon Arkell: Guided the strategic direction and rebranding of the company.

• Chadi Nabhan: Oversees medical strategy and partnerships, including collaborations with academic institutions.

• Johnny Crupi: Leads technological development, including the integration of AI technologies.

Leadership Changes

Recent Appointments

• Tarek Sherif: Co-founder and former CEO of Medidata Solutions, joined Ryght as an investor and advisor in October 2024.

Competitor Profile

Market Insights and Dynamics

The clinical research industry is evolving with increasing adoption of AI technologies to address inefficiencies. The market is expanding as organizations seek solutions to accelerate trial timelines and improve data accuracy.

Competitor Analysis

• Medidata Solutions: Offers cloud-based solutions for clinical trials; acquired by Dassault Systèmes in 2019.

• Parexel International: Provides comprehensive drug development and regulatory consulting services.

• Celerion: Specializes in clinical pharmacology and early clinical research.

Strategic Collaborations and Partnerships

• QPS Holdings, LLC: Partnered in January 2025 to optimize and automate global clinical trials.

• University of Southern California (USC): Joined the Ryght Research Network in December 2024.

• Medical College of Wisconsin: Became a member of the Ryght Research Network in April 2025.

Operational Insights

Ryght differentiates itself through its AI-driven platform, AI Site Twins, and strategic partnerships, positioning it as a leader in clinical trial optimization.

Strategic Opportunities and Future Directions

Strategic Roadmap

• Product Expansion: Develop additional AI applications to address broader clinical research needs.

• Global Network Growth: Expand the Ryght Research Network to include more academic and community sites worldwide.

• Regulatory Compliance: Ensure all solutions meet global data security and privacy standards.

Future Business Directions

• AI Integration: Integrate advanced AI capabilities into all aspects of clinical research.

• Market Penetration: Increase presence in emerging markets with growing clinical research activities.

Opportunities for Expansion

• Therapeutic Areas: Extend solutions to additional therapeutic areas beyond oncology.

• Geographical Reach: Enter new international markets to broaden the user base.

Contact Information

• Official Website: www.ryght.ai

• LinkedIn: Ryght AI